Compugen Ltd. has never declared or distributed cash dividend payments to its common shareholders. As a clinical-stage biotechnology and computational drug discovery enterprise, the company consistently reinvests all available financial capital and partnering revenues directly into its research and development programs, preclinical discovery platforms, and ongoing clinical trial pipelines. Management maintains a growth-oriented capital allocation strategy focused on advancing therapeutic candidates rather than establishing regular income distributions or dividend yields.